- DermTech (DMTK) has transformative solutions that are more effective and accurate than traditional biopsy-based diagnostic approaches for detecting Skin Cancer.
- Commercialization of its proprietary SmartSticker solution has been slow, despite recent significant investments in the company’s salesforce.
- Although the company’s solutions have enormous potential and could drive the stock price significantly higher if successfully commercialized, recent management guidance for the next 12 months was soft.
- The future outcome for DMTK may be binary - either massive success driven by mass product adoption or a slow fade to oblivion based on failed commercialization.
For further details see:
DermTech: Approaching An All Or Nothing Moment